155 related articles for article (PubMed ID: 10102344)
1. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.
Niezabitowski A; Czajecki K; Ryś J; Kruczak A; Gruchała A; Wasilewska A; Lackowska B; Sokołowski A; Szklarski W
J Surg Oncol; 1999 Mar; 70(3):150-60. PubMed ID: 10102344
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities].
Nepomniashchaia EM; Gusareva MA; Petrov SV
Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851
[TBL] [Abstract][Full Text] [Related]
3. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
5. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
7. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin.
Talve LA; Collan YU; Ekfors TO
J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921
[TBL] [Abstract][Full Text] [Related]
8. Melastatin expression and prognosis in cutaneous malignant melanoma.
Duncan LM; Deeds J; Cronin FE; Donovan M; Sober AJ; Kauffman M; McCarthy JJ
J Clin Oncol; 2001 Jan; 19(2):568-76. PubMed ID: 11208852
[TBL] [Abstract][Full Text] [Related]
9. Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma.
Martin G; Halwani F; Shibata H; Meterissian S
Can J Surg; 2000 Feb; 43(1):29-34. PubMed ID: 10714254
[TBL] [Abstract][Full Text] [Related]
10. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
11. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between tumor cell proliferation and prognosis of primary cutaneous malignant melanoma in 127 patients].
Wang Y; Xue WC; Si L; Cui CL; Lu AP; Cao DF; Guo J; Li ZW
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):178-81. PubMed ID: 23769437
[TBL] [Abstract][Full Text] [Related]
13. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
14. Cytomorphological variations, proliferation and angiogenesis in the prognosis of cutaneous melanoma.
Jonjic N; Zamolo G; Stifter S; Fuckar D; Gruber F; Sasso F; Rizzardi C; Melato M
Clin Exp Dermatol; 2003 May; 28(3):310-4. PubMed ID: 12780721
[TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract].
An JS; Wu LY; Li N; Li B; Yu GZ; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):320-4. PubMed ID: 17673044
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
17. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PCNA grade in malignant melanoma.
Woosley JT; Dietrich DR
J Cutan Pathol; 1993 Dec; 20(6):498-503. PubMed ID: 7907615
[TBL] [Abstract][Full Text] [Related]
19. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases.
Carlson JA; Dickersin GR; Sober AJ; Barnhill RL
Cancer; 1995 Jan; 75(2):478-94. PubMed ID: 7812919
[TBL] [Abstract][Full Text] [Related]
20. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.
Lohmann CM; Iversen K; Jungbluth AA; Berwick M; Busam KJ
Am J Surg Pathol; 2002 Oct; 26(10):1351-7. PubMed ID: 12360050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
